Dupont Jakob sold $107K of PYXS
Dupont Jakob sold 35,000 shares of Pyxis Oncology, Inc. (PYXS) at $3.06 ($0.11M total) on 2026-06-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s scheduled open-market sale of 35,000 shares at $3.06, totaling $107,100, with holdings after the trade of 38,741 shares.
Market read
Traders may monitor for follow-on insider activity, but the disclosure alone does not change the company’s near-term fundamentals.
What to watch
The article provides no context on total holdings, prior sales cadence, or whether other insiders are selling/buying, limiting inference from this single transaction.
Background
The article is a SEC Form 4 insider transaction disclosure for Pyxis Oncology, Inc.
Ticker impact
Pyxis Oncology director Dupont Jakob filed a Form 4 selling 35,000 shares at $3.06 on June 30 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited to near-term sentiment around insider selling.
The filing is a routine 10b5-1 open-market sale by a director, with no accompanying company-specific news (earnings, guidance, trials, deals, or regulatory actions) in the text.
Market effects
Minimal. Insider sale in a single biotech does not provide sector-wide signal in the provided text.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerPyxis Oncology, Inc.
Subject of the Form 4 insider transaction disclosure (PYXS).
- insiderDupont Jakob
Director who executed the reported open-market sale under a 10b5-1 plan.